Abstracts tagged "methotrexate (MTX) and rheumatoid arthritis"

Abstract Number: 597 • 2018 ACR/ARHP Annual Meeting
Characteristics of Patients and Predictors of Composite Disease Activity Scores for Switching to Monotherapy Vs Continuing TNF Inhibitor and Methotrexate Combination Therapy in RA: A Retrospective Analysis of the Brigham and Women’s Rheumatoid Arthritis Sequential Study Registry
Nancy A. Shadick¹, Michael E Weinblatt¹, Christine K Iannaccone², Michelle Frits³, Tigwa Davis⁴, Christopher Young⁴, David H. Collier⁵, Mahdi Gharaibeh⁵ and Bradley S. Stolshek⁶, ¹Brigham and Women's Hospital, Boston, MA, ²Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴Health Analytics, LLC, Columbia, MD, ⁵Amgen Inc., Thousand Oaks, CA, ⁶Amgen, Inc., Thousand Oaks, CA
Background/Purpose: Biologics in combination with methotrexate (MTX) are being incorporated earlier in rheumatoid arthritis (RA) therapy to prevent long-term damage and maintain patient function. While…
Abstract Number: 929 • 2018 ACR/ARHP Annual Meeting
Transcriptional Profiling of the Subcutaneous Rheumatoid Nodule: An Insight into Pathogenic Mechanisms and Cellular Content
Judith Marsman¹, Melanie J Millier¹, John Highton¹, Lisa K. Stamp² and Paul A Hessian¹, ¹Department of Medicine, University of Otago, Dunedin, New Zealand, ²University of Otago, Christchurch, New Zealand
Background/Purpose: Rheumatoid nodules are the most common cutaneous manifestation in patients with RA, often associated with longstanding and a more severe disease course. Paradoxically, therapy…
Abstract Number: 2822 • 2018 ACR/ARHP Annual Meeting
Should We Prefer Leflunomide to Methotrexate in Combination with Biologics? a Systematic Review and a Meta-Analysis
Guillaume Decarriere¹, Thomas Barnetche², Cédric Lukas³, Cécile Gaujoux-Viala⁴, Bernard Combe⁵, Jacques Morel⁶ and Claire I. Daien⁷, ¹Department of Rheumatology, CHU Lapeyronie, Montpellier, France, ²Rheumatology Department, FHU ACRONIM, Bordeaux University Hospital, Bordeaux, France, ³Rheumatology, CHU Lapeyronie and EA2415, Montpellier University, University of Montpellier, France, ⁴Rheumatology, Nîmes University Hospital and EA2415 Montpellier University, Nîmes, France, ⁵Rheumatology, University Hospital Lapeyronie, Montpellier, Montpellier, France, ⁶Department of Rheumatology, University Hospital Lapeyronie, Montpellier, Montpellier, France, ⁷Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France
Background/Purpose: In rheumatoid arthritis (RA), biologics are more efficient in combination with methotrexate (MTX) than in monotherapy. When MTX cannot be used, others csDMARD can…
Abstract Number: 1445 • 2017 ACR/ARHP Annual Meeting
Effect of Methotrexate (MTX), and MTX Plus Colchicine (CCH) on the Expression and Activity of NLRP3 Inflammasome in Patients with Early Rheumatoid Arthritis (RA)
Dolores Ramos-Bello¹, Crisol Alvarez-Quiroga², Georgina Aguilera Barragán-Pickens³, Angel Javier Pedro Martínez³, Tania Adriana Luna-Zúñiga³, Georgina Martínez-Flores³, Eduardo Saul Acevedo-Castañeda⁴, Homero López-Ferretis³, Enrique Cuevas-Orta³, Eva Santillan-Guerrero³, Ricardo Moreno-Valdez³, Martín Saldaña-Baarnard³, Marco Ulises Martinez-Martinez⁵, David Herrera Van Oostdam⁶, Roberto González-Amaro⁷ and Carlos Abud-Mendoza⁸, ¹Reumatología, Unidad Regional de Reumatologia y Osteoporosis Hospital Central "Dr. Ignacio Morones Prieto" y Facultad de Medicina de la UASLP, San Luis Potosi, Mexico, ²División de Medicina Molecular y Traslacional, Centro de Investigación en Ciencias de la Salud y Biomedicina, UASLP, San Luis Potosí, Mexico, ³Unidad Regional de Reumatologia y Osteoporosis Hospital Central "Dr. Ignacio Morones Prieto" y Facultad de Medicina de la UASLP, San Luis Potosí, Mexico, ⁴Medicina Interna, Unidad Regional de Reumatologia y Osteoporosis Hospital Central "Dr. Ignacio Morones Prieto" y Facultad de Medicina de la UASLP, San Luis Potosí, Mexico, ⁵Unidad de Investigaciones Reumatológicas, Faculty of Medicine, Universidad Autónoma de San Luis Potosí and Hospital Central, San Luis Potosí, Mexico, ⁶Unidad de Investigaciones Reumatológicas, Hospital Central & Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, ⁷Inmunología, Facultad de Medicina de la UASLP, San Luis Potosí, Mexico, ⁸Unidad de Investigaciones Reumatológicas y Osteoporosis, Faculty of Medicine, Universidad Autónoma de San Luis Potosí and Hospital Central, San Luis Potosí, Mexico
Background/Purpose: NLRP3 inflammasome is an intracellular protein complex involved in the production of pro-inflammatory cytokines as IL-1β and IL-18, which has been reported to have…
Abstract Number: 2535 • 2016 ACR/ARHP Annual Meeting
Effect of Methotrexate in the Presence of Drug and the Appearance of Antibodies Against Tumour Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis
Chamaida Plasencia-Rodriguez¹, Ana Martínez², Alejandro Villalba³, Teresa Jurado⁴, Eva Olariaga-Merida⁵, Araceli Mezcua⁶, Diana Peiteado³, Gema Bonilla³, Laura Nuño³, Alejandro Balsa¹ and Dora Pascual-Salcedo², ¹Instituto de Investigación Hospital Universitario La Paz (IDIPAZ), Madrid, Spain, ²Immunology Unit, La Paz University Hospital-Immunology, Madrid, Spain, ³Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, ⁴Immunology Unit, La Paz University Hospital-IdiPaz, MADRID, Spain, ⁵Immunology, University Hospital La Paz, Madrid, Spain, ⁶Immunology Unit, La Paz University Hospital, Madrid, Spain
Background/Purpose: Several factors influence pharmacokinetics of TNFinhibitors (TNFi). One relevant factor is the formation of anti drug- antibodies (ADA) associated with low drug levels and…
Abstract Number: 611 • 2015 ACR/ARHP Annual Meeting
The Rapid Kinetics of Optimal Treatment with Subcutaneous Methotrexate in Early Inflammatory Arthritis
Anna O'Connor¹, J Carter Thorne², Diane Tin³ and Janet E. Pope⁴, ¹Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ⁴Monsignor Roney Bldg/Rheum, University of Western Ontario, St Joseph Health Care, London, ON, Canada
Background/Purpose: Methotrexate (MTX) is standard treatment in RA. Absorption is better in subcutaneous MTX (scMTX), which may impact speed of onset. In RA, earlier time…
Abstract Number: 1659 • 2015 ACR/ARHP Annual Meeting
Lack of Effect of Reduced Folic Acid Supplementation on Disease Activity in RA
Lisa K. Stamp¹, Jill Drake², John L. O'Donnell³, Christopher Frampton⁴ and Peter T. Chapman⁵, ¹Medicine, University of Otago, Christchurch, Christchurch, New Zealand, ²Rheumatology, Immunology and Allergy, Christchurch Hospital, Christchurch, New Zealand, ³Immunology, Canterbury Health Laboratories, Christchurch, New Zealand, ⁴University of Otago, Christchurch, Christchurch, New Zealand, ⁵Rheumatology, Christchurch Hospital, Christchurch, New Zealand
Background/Purpose: It is recommended that all patients receiving MTX also receive at least 5mg/week of folic acid in an effort to reduce occurrence of MTX…
Abstract Number: 1665 • 2015 ACR/ARHP Annual Meeting
Treatment Patterns in Rheumatoid Arthritis after Methotrexate: Data from a Rheumatoid Arthritis Cohort
Janet E. Pope¹, Mohammad Movahedi^2,3, Angela Cesta², Xiuying Li², Sandra Couto², Emmanouil Rampakakis³, John S. Sampalis^3,4, Claire Bombardier^2,5,6 and OBRI Investigators, ¹University of Western Ontario, London, ON, Canada, ²Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ³JSS Medical Research, St-Laurent, QC, Canada, ⁴McGill University, Montreal, QC, Canada, ⁵University of Toronto, Department of Medicine (DOM) and Institute of Health Policy Management, and Evaluation (IHPME), Toronto, ON, Canada, ⁶Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Guidelines support the use of combination conventional synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs), switching csDMARDs and/or use of biologic DMARDs (bDMARDs) treatment in active rheumatoid…
Abstract Number: 2223 • 2013 ACR/ARHP Annual Meeting
Monitoring Of Active Matrix Metalloproteinase-3 Using
Sung Jae Choi¹, Young Ho Seo², Young Ho Lee³, Jong Dae Ji¹, Gwan Gyu Song⁴, Aeju Lee² and Jae-Hoon Kim⁴, ¹Rheumatology, Korea University Medical Center, Seoul, South Korea, ²Rheumatology, Korea University Medical center, Seoul, South Korea, ³Internal Medicine, Rheumatology, Korea University Medical Center, Seoul, South Korea, ⁴Div of Rheum, Dept of Int Med, Korea Univ College of Med, Seoul, South Korea
Background/Purpose: Active matrix metalloproteinase-3 (MMP-3) is a prognostic marker of rheumatoid arthritis (RA). Recently, we developed the MMP-3 probe which can specifically detect an active…
Abstract Number: 1337 • 2013 ACR/ARHP Annual Meeting
Nearly Pain Free Self-Administration Of Methotrexate Using An Investigational Auto-Injector: Results Of a Phase-2 Clinical Trial In Rheumatoid Arthritis Patients With Mild-To-Severe Functional Limitations
Alan J. Kivitz¹, David McLain², John Hill³, Bruce Freundlich⁴, Jonathan Jaffe⁵ and Kaushik J. Dave⁶, ¹Altoona Center for Clinical Research, Duncansville, PA, ²Rheumatology, McLain Medical Associates, PC, Birmingham, AL, ³Avail Clinical Research, DeLand, FL, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Clinical Development, Antares Pharma Inc, Ewing, NJ, ⁶Product Development, Antares Pharma Inc, Ewing, NJ
Background/Purpose: Methotrexate (MTX) is the cornerstone of rheumatoid arthritis (RA) treatment. Limitations of systemic exposure of oral MTX can affect its efficacy. Subcutaneous (SC) MTX…
Abstract Number: 796 • 2013 ACR/ARHP Annual Meeting
Drug Exposure Limitations of Oral Methotrexate (MTX) At Doses >15mgs May be Overcome By Using a Subcutaneous MTX Auto-Injector in Patients With Rheumatoid Arthritis (RA)
Michael H. Schiff¹, Lee S. Simon², Bruce Freundlich³, Jonathan Jaffe⁴ and Kaushik J. Dave⁵, ¹Rheumatology Division, University of Colorado, Denver, CO, ²SDG LLC Consulting, West Newton, MA, ³University of Pennsylvania, Philadelphia, PA, ⁴Clinical Development, Antares Pharma Inc, Ewing, NJ, ⁵Product Development, Antares Pharma Inc, Ewing, NJ
Drug exposure limitations of oral methotrexate (MTX) at doses >15mgs may be overcome by using a subcutaneous MTX auto-injector in pts with rheumatoid arthritis (RA) Background/Purpose:…
Abstract Number: 2313 • 2013 ACR/ARHP Annual Meeting
Pain-Related Anxiety As a Barrier To Use Of Methotrexate In Rheumatoid Arthritis: Comparing Conventional Vial, Needles, and Syringe With An Investigational Auto-Injector In Healthy Volunteers
Victoria L. Ruffing¹ and Kaushik J. Dave², ¹Medicine JHAAC, Johns Hopkins University, Baltimore, MD, ²Product Development, Antares Pharma Inc, Ewing, NJ
Background/Purpose: Methotrexate (MTX) is the cornerstone of rheumatoid arthritis (RA) treatment. Limitations of systemic exposure of oral MTX can affect its efficacy. Subcutaneous (SC) MTX…
Abstract Number: 2324 • 2013 ACR/ARHP Annual Meeting
Persistence On Biologics Is Associated With Concomitant Methotrexate Use Among Rheumatoid Arthritis Patient
Jie Zhang¹, Fenglong Xie², Elizabeth S. Delzell³, Huifeng Yun³, James Lewis⁴, Kevin Haynes⁵, Lang Chen⁶ and Jeffrey R. Curtis⁷, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁴Medicine, University of Pennsylvania, Philadelphia, PA, ⁵Clinical Epidemiology and Biostatistics, University of Pennsylvania., Philadelphia, PA, ⁶Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁷University of Alabama at Birmingham, Birmingham, AL
Persistence on Biologics is Associated with Concomitant Methotrexate Use among Rheumatoid Arthritis Patient Background/Purpose: Concomitant methotrexate (MTX) is associated with improved treatment efficacy in randomized controlled…
Abstract Number: 1322 • 2012 ACR/ARHP Annual Meeting
Coadministration of ASP015K, a Novel Janus Kinase Inhibitor with Methotrexate Demonstrates Tolerability and Lack of Pharmacokinetic Interactions in Patients with Rheumatoid Arthritis
Tong Zhu¹, Kazuo Oda², Udaya Valluri¹, Bogie Moore¹, Ying Cao¹, Vishala Chindalore³ and Bola Akinlade⁴, ¹Astellas Pharma Global Development, Inc., Northbrook, IL, ²Drug Metabolism Research Labs. Drug Discovery Research, Astellas Pharma Inc., Osaka, Japan, ³Pinnacle Research Group/Anniston Medical Clinic, Anniston, AL, ⁴Immunology Development, Astellas Pharma Global Development, Inc., Northbrook, IL
Background/Purpose: ASP015K is an oral Janus kinase (JAK) inhibitor with selectivity for JAK1/3 in development for treatment of rheumatoid arthritis (RA) and other autoimmune diseases.…
Abstract Number: 996 • 2012 ACR/ARHP Annual Meeting
Genetic Predictors of Methotrexate Efficacy and Toxicity in Early Rheumatoid Arthritis: Results From the Treatment of Early Aggressive Rheumatoid Arthritis Trial
Stella Aslibekyan¹, Elizabeth Brown², Richard J. Reynolds³, David T. Redden⁴, Sarah L. Morgan⁵, Joseph Baggott¹, Jin Sha¹, Larry W. Moreland⁶, James R. O'Dell⁷, Jeffrey R. Curtis⁸, S. Louis Bridges Jr.⁹ and Donna K. Arnett¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Univ of Alabama at Birmingham, Birmingham, AL, Birmingham, AL, ³Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Biostatistics, University of Alabama at Birmingham, Birmingham, AL, ⁵University of Alabama Birmingham, Birmingham, AL, ⁶Division of Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁷Dept of Internal Medicine, Univ of Nebraska Med Ctr, Omaha, NE, ⁸Rheumatology & Immunology, Univ of Alabama-Birmingham, Birmingham, AL, ⁹Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Methotrexate (MTX) has emerged as first-line therapy for early moderate to severe rheumatoid arthritis (RA), but individual variation in treatment efficacy and toxicity remains…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].